Call Options

9 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$6.23 - $9.51 $1,246 - $1,902
-200 Reduced 11.76%
1,500 $10,000
Q2 2024

Aug 14, 2024

SELL
$5.9 - $8.02 $14,750 - $20,050
-2,500 Reduced 59.52%
1,700 $11,000
Q1 2024

May 15, 2024

BUY
$7.5 - $12.07 $17,250 - $27,761
2,300 Added 121.05%
4,200 $34,000
Q4 2023

Feb 14, 2024

SELL
$6.01 - $11.48 $32,454 - $61,992
-5,400 Reduced 73.97%
1,900 $20,000
Q3 2023

Nov 14, 2023

SELL
$8.24 - $12.97 $13,184 - $20,752
-1,600 Reduced 17.98%
7,300 $61,000
Q2 2023

Aug 14, 2023

SELL
$9.99 - $18.27 $161,838 - $295,974
-16,200 Reduced 64.54%
8,900 $111,000
Q1 2023

May 15, 2023

BUY
$15.0 - $22.76 $256,500 - $389,196
17,100 Added 213.75%
25,100 $413,000
Q4 2022

Feb 14, 2023

SELL
$14.16 - $24.02 $2.32 Million - $3.93 Million
-163,800 Reduced 95.34%
8,000 $119,000
Q3 2022

Nov 14, 2022

SELL
$18.07 - $31.37 $1.21 Million - $2.1 Million
-66,900 Reduced 28.03%
171,800 $3.84 Million

Others Institutions Holding RLAY

About Relay Therapeutics, Inc.


  • Ticker RLAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 120,219,000
  • Market Cap $509M
  • Description
  • Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...
More about RLAY
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.